A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy

Imagem de Miniatura
Arquivos
art_FUJIHARA_A_Novel_Aldosterone_Antagonist_Limits_Renal_Injury_in_2017.PDF (2.65 MB)
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
KOWALA, M. C.
BREYER, M. D.
JADHAV, P. K.
MONTROSE-RAFIZADEH, Chahrzad
Citação
SCIENTIFIC REPORTS, v.7, article ID 7899, 12p, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aldosterone antagonists slow the progression of chronic kidney disease (CKD), but their use is limited by hyperkalemia, especially when associated with RAS inhibitors. We examined the renoprotective effects of Ly, a novel non-steroidal mineralocorticoid receptor (MR) blocker, through two experimental protocols: In Protocol 1, male Munich-Wistar rats underwent 5/6 renal ablation (Nx), being divided into: Nx+V, receiving vehicle, Nx+Eple, given eplerenone, 150 mg/kg/day, and Nx+Ly, given Ly, 20 mg/kg/day. A group of untreated sham-operated rats was also studied. Ly markedly raised plasma renin activity (PRA) and aldosterone, and exerted more effective anti-albuminuric and renoprotective action than eplerenone. In Protocol 2, Nx rats remained untreated until Day 60, when they were divided into: Nx+V receiving vehicle; Nx+L treated with losartan, 50 mg/kg/day; Nx+L+Eple, given losartan and eplerenone, and Nx+L+Ly, given losartan and Ly. Treatments lasted for 90 days. As an add-on to losartan, Ly normalized blood pressure and albuminuria, and prevented CKD progression more effectively than eplerenone. This effect was associated with strong stimulation of PRA and aldosterone. Despite exhibiting higher affinity for the MR than either eplerenone or spironolactone, Ly caused no hyperkalemia. Ly may become a novel asset in the effort to detain the progression of CKD.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/22009
Referências
  1. Arias SCA, 2016, AM J PHYSIOL-RENAL, V310, pF135, DOI 10.1152/ajprenal.00388.2015
  2. Arias SCA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056215
  3. Aldigier JC, 2005, J AM SOC NEPHROL, V16, P3306, DOI 10.1681/asn.2004090804
  4. ALNEMRI ES, 1991, J BIOL CHEM, V266, P18072
  5. Bakris GL, 2015, JAMA-J AM MED ASSOC, V314, P884, DOI 10.1001/jama.2015.10081
  6. Beasley TM, 1995, J EXP EDUC, V64, P79
  7. Bianchi S, 2015, INT J CARDIOL, V200, P20, DOI 10.1016/j.ijcard.2015.05.125
  8. BINART N, 1991, P NATL ACAD SCI USA, V88, P10681, DOI 10.1073/pnas.88.23.10681
  9. Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161
  10. Brown NJ, 2013, NAT REV NEPHROL, V9, P459, DOI 10.1038/nrneph.2013.110
  11. Chen H, 2013, KIDNEY BLOOD PRESS R, V37, P557, DOI 10.1159/000355736
  12. CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
  13. Fujihara CK, 2000, J AM SOC NEPHROL, V11, P283
  14. Fujihara CK, 2007, AM J PHYSIOL-RENAL, V292, pF1810, DOI 10.1152/ajprenal.00521.2006
  15. Fujisaki K, 2014, HYPERTENS RES, V37, P993, DOI 10.1038/hr.2014.110
  16. GUYTON AC, 1991, SCIENCE, V252, P1813, DOI 10.1126/science.2063193
  17. Haller H, 2016, CURR HYPERTENS REP, V18, DOI 10.1007/s11906-016-0649-2
  18. Ikeda H, 2009, KIDNEY INT, V75, P147, DOI 10.1038/ki.2008.507
  19. JEPSEN FL, 1979, VIRCHOWS ARCH A, V383, P265, DOI 10.1007/BF00430245
  20. Joyeux A, 1997, ANAL BIOCHEM, V249, P119, DOI 10.1006/abio.1997.2147
  21. Kim HY, 2014, KIDNEY BLOOD PRESS R, V39, P573, DOI 10.1159/000368470
  22. Kolkhof P, 2015, CURR OPIN NEPHROL HY, V24, P417, DOI 10.1097/MNH.0000000000000147
  23. Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303
  24. Meyers MJ, 2010, J MED CHEM, V53, P5979, DOI 10.1021/jm100505n
  25. Nagai Y, 2005, HYPERTENSION, V46, P1039, DOI 10.1161/01.HYP.0000174593.88899.68
  26. Nagase M, 2006, J AM SOC NEPHROL, V17, P3438, DOI 10.1681/ASN.2006080944
  27. Nemeth Z, 2009, NEPHROL DIAL TRANSPL, V24, P3640, DOI 10.1093/ndt/gfp371
  28. Nielsen SE, 2012, DIABETIC MED, V29, pE184, DOI 10.1111/j.1464-5491.2012.03585.x
  29. Piecha G, 2008, AM J PHYSIOL-RENAL, V295, pF137, DOI 10.1152/ajprenal.00065.2008
  30. Pitt B, 2013, EUR HEART J, V34, P2453, DOI 10.1093/eurheartj/eht187
  31. Rodriguez-Iturbe B, 2002, AM J PHYSIOL-RENAL, V282, pF191
  32. Schjoedt KJ, 2005, KIDNEY INT, V68, P2829, DOI 10.1111/j.1523-1755.2005.00756.x
  33. Schrier RW, 2010, NAT REV NEPHROL, V6, P61, DOI 10.1038/nrneph.2009.228
  34. Spat A, 2004, MOL CELL ENDOCRINOL, V217, P23, DOI 10.1016/j.mce.2003.10.046
  35. Tait JF, 1999, CLIN EXP PHARMACOL P, V26, P947, DOI 10.1046/j.1440-1681.1999.03173.x
  36. WALLENSTEIN S, 1980, CIRC RES, V47, P1

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/13
Carregar mais